Penn Uterine Transplantation for Uterine Factor Infertility (UNTIL) Trial

Site Image

Study Overview

The UNTIL Trial is a new clinical research trial that offers uterine transplantation to women with uterine factor infertility (UFI). Participation in this trial requires going through an extensive selection process, creation of embryos through in vitro fertilization, and multiple surgeries. Study participants may remain in the study for 5-10 years after the transplant.

Study Description

UFI is an irreversible form of female infertility that affects as many as 5% of women worldwide. A woman with UFI cannot carry a pregnancy either because she was born without a uterus, has had the uterus surgically removed, or has a uterus that does not function. Uterine transplant is a highly experimental procedure that offers women with UFI their only chance to carry a pregnancy. However, a uterine transplant is not for everyone and your physician may recommend other forms of treatment including use of a gestational carrier (surrogate) or adoption before deciding a uterus transplant is right for you. At present only 8 babies have been born to women who underwent uterine transplantation in the world. Candidates will undergo an extensive evaluation by a team of physicians, psychologists, nurses and social workers – the evaluation is extensive since women will undergo multiple surgeries and in vitro fertilization (IVF) as part of this trial. Following uterine transplant women cannot become pregnant without assistance. Therefore, prior to undergoing uterine transplant, embryos must be created through IVF. IVF requires stimulation of the woman’s ovaries to produce multiple eggs. This is followed by removal of the eggs and fertilization of the eggs with sperm in the IVF lab. Embryos that are created are frozen for later use. The UNTIL trial will use a donor uterus from an unrelated deceased donor for transplantation. Deceased donors are individuals who die from accidents, medical conditions or other events, and either they or their next of kin consent to donating their organs to individuals in need. All organ transplant require the recipient take anti-rejection medications to prevent the body from attacking the transplant. Women in this study will be on anti-rejection drugs for as long as they retain the uterus. After the transplant surgery, the physicians conducting the study will monitor the recipients carefully and frequently for one year for any complications such as infection or rejection. Once the uterus heals and is functioning, with no infections or rejection episodes that could not be treated, a single embryo is put back into the uterus. When a pregnancy is achieved, the pregnancy is monitored closely by a team of high-risk obstetricians and the recipient will continue to take anti-rejection medications for the duration of the pregnancy. These medications may have effects on the developing baby.The baby will be delivered via C-section (about 37 weeks) or earlier if needed for the health of the mother and/or baby. To date, all of the babies born to women who have had uterine transplants have been born early (most between 35-37 weeks). After the recipient has delivered 1 or 2 healthy babies the uterus is removed (hysterectomy) and anti-rejection medications are stopped.

Additional Information:

Candidates must be: 1) Women between the ages of 21 and 40 with UFI and 2) Live in or near the Philadelphia area for the duration of the study. Contact the Penn UNTIL Nurse Study Coordinator for a full list of details regarding who is eligible to participate in this trial. Importantly, to date all of the babies that have been born following uterine transplantation have been born from one center in Sweden and have been born to women who received a uterus from a living friend or family member who had completed their childbearing ("living donor model"). In the UNTIL trial we will be performing uterine transplants from deceased donors rather than living donors. No children have been born after undergoing uterine transplantation with a uterus from a deceased donor yet. If you are interested in participating in the UNTIL trial please complete the Participant Eligibility Screener by pasting this link into your browser:

  • Study Identifier: 827853

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email